| References |
1. Maruoka D, Arai M, Tanaka T, Okimoto K, Oyamada A, Minemura S, Tsuboi M, Matsumura T, Nakagawa T, Kanda T, Katsuno T, Imazeki F, Yokosuka O. Mosapride citrate increases postprandial glucagon-like peptide-1, insulin, and gene expression of sweet taste receptors. Dig Dis Sci. 2015 Feb;60(2):345-53. doi: 10.1007/s10620-014-3271-7. Epub 2014 Jul 10. PubMed PMID: 25008428. 2. Kim YH, Bae YJ, Kim HS, Cha HJ, Yun JS, Shin JS, Seong WK, Lee YM, Han KM. Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay. Biomol Ther (Seoul). 2015 Sep;23(5):486-92. doi: 10.4062/biomolther.2015.041. Epub 2015 Sep 1. PubMed PMID: 26336590; PubMed Central PMCID: PMC4556210. 3. Okubo H, Nakatsu Y, Sakoda H, Kushiyama A, Fujishiro M, Fukushima T, Matsunaga Y, Ohno H, Yoneda M, Kamata H, Shinjo T, Iwashita M, Nishimura F, Asano T. Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015 Jan 15;308(2):G151-8. doi: 10.1152/ajpgi.00198.2014. Epub 2014 Nov 26. PubMed PMID: 25428903. 4. Aoki K, Kamiyama H, Masuda K, Togashi Y, Terauchi Y. Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men. Endocr J. 2013;60(4):493-9. Epub 2012 Dec 18. PubMed PMID: 23257734. |
